Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients

References

• Hamblin T. Chronic lymphocytic leukaemia: one disease or two? Ann.Hematol 2002; 81:299-303
   Web of Science ®Google Scholar
• Van Bockstaele F, Verhasselt B, Philippe J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009; 23:25-47; PMID:18599169; http://dx.doi.org/10.1016/j.blre.2008.05.003
   PubMed Web of Science ®Google Scholar
• Workman JL, Kingston RE. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu.Rev.Biochem 1998; 67:545-579; http://dx.doi.org/10.1146/annurev.biochem.67.1.545
   PubMed Web of Science ®Google Scholar
• Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009; 277:8-21; PMID:18824292; http://dx.doi.org/10.1016/j.canlet.2008.08.016
   PubMed Web of Science ®Google Scholar
• Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009; 280:168-176; PMID:19103471; http://dx.doi.org/10.1016/j.canlet.2008.10.047
   PubMed Web of Science ®Google Scholar
• Secrist JP, Zhou X, Richon VM. HDAC inhibitors for the treatment of cancer. Curr Opin Investig Drugs 2003; 4:1422-1427; PMID:14763127
   PubMedGoogle Scholar
• Stamatopoulos B, Meuleman N, De Bruyn C et al. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 2009; 23:2281-2289; PMID:19710697; http://dx.doi.org/10.1038/leu.2009.176
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Meuleman N, De Bruyn C et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica 2010; 95:1136-1143; PMID:20145270; http://dx.doi.org/10.3324/haematol.2009.013847
   PubMed Web of Science ®Google Scholar
• Van Damme M, Crompot E, Meuleman N et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics. 2012; 7:1403-1412; PMID:23108383; http://dx.doi.org/10.4161/epi.22674
   PubMed Web of Science ®Google Scholar
• Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998; 91:2387-2396; PMID:9516138
   PubMed Web of Science ®Google Scholar
• Scielzo C, Apollonio B, Scarfo L et al. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia 2011; 25:1760-1767; PMID:21709686; http://dx.doi.org/10.1038/leu.2011.149
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Polliack A. B-cell receptor signaling in chronic lymphocytic leukemia leans on Lyn. Leuk Lymphoma 2013; 54:1125-1126; PMID:23270582; http://dx.doi.org/10.3109/10428194.2012.754097
   PubMed Web of Science ®Google Scholar
• Vlad A, Deglesne PA, Letestu R et al. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res 2009; 69:6387-6395; PMID:19654311; http://dx.doi.org/10.1158/0008-5472.CAN-08-4750
   PubMed Web of Science ®Google Scholar
• Ronzoni S, Faretta M, Ballarini M, Pelicci P, Minucci S. New method to detect histone acetylation levels by flow cytometry. Cytometry A 2005; 66:52-61; PMID:15915507; http://dx.doi.org/10.1002/cyto.a.20151
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37:391-400; PMID:15765097; http://dx.doi.org/10.1038/ng1531
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124:30-39; PMID:24382387; http://dx.doi.org/10.1172/JCI69738
   PubMed Web of Science ®Google Scholar
• Van Meter M, Mao Z, Gorbunova V, Seluanov A. SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle 2011; 10:3153-3158; PMID:21900744; http://dx.doi.org/10.4161/cc.10.18.17435
   PubMed Web of Science ®Google Scholar
• Inoue T, Hiratsuka M, Osaki M, Oshimura M. The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 2007; 6:1011-1018; PMID:17457050; http://dx.doi.org/10.4161/cc.6.9.4219
   PubMed Web of Science ®Google Scholar
• Matthews SA, Liu P, Spitaler M et al. Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes. Mol.Cell Biol 2006; 26:1569-1577.
   Web of Science ®Google Scholar
• Fischle W, Dequiedt F, Hendzel MJ et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 2002; 9:45-57; PMID:11804585; http://dx.doi.org/10.1016/S1097-2765(01)00429-4
   PubMed Web of Science ®Google Scholar
• Lahm A, Paolini C, Pallaoro M et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A 2007; 104:17335-17340; PMID:17956988; http://dx.doi.org/10.1073/pnas.0706487104
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Perez G, Xu W et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol.Cancer Ther 2007; 6:2525-2534; http://dx.doi.org/10.1158/1535-7163.MCT-07-0251
   Google Scholar
• Hubbert C, Guardiola A, Shao R et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417:455-458; PMID:12024216; http://dx.doi.org/10.1038/417455a
   PubMed Web of Science ®Google Scholar
• Kovacs JJ, Murphy PJ, Gaillard S et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18:601-607; PMID:15916966; http://dx.doi.org/10.1016/j.molcel.2005.04.021
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Meuleman N, Haibe-Kains B et al. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Clin.Chem. 2007; 53:1757-1766;
   Google Scholar
• Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br.J Haematol 1986; 62:567-575; http://dx.doi.org/10.1111/j.1365-2141.1986.tb02969.x
   Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N.Engl J Med 2000; 343:1910-1916; http://dx.doi.org/10.1056/NEJM200012283432602
   PubMed Web of Science ®Google Scholar
• Cuneo A, Rigolin GM, Bigoni R et al. Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. Leukemia 2004; 18:476-483; PMID:14712287; http://dx.doi.org/10.1038/sj.leu.2403242
   PubMed Web of Science ®Google Scholar